Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Otilonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL22324606 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22323711 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22324597 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22323864 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22324511 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22324509 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22324633 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Bromide SCHEMBL22323721 | 1.00 | NR1I2 (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Otilonium SCHEMBL31646954 | 0.99 | KMT2A (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 | |
| Otilonium SCHEMBL20352274 | 0.99 | KMT2A (1.00) | NR1I2CHRM2OPRK1HTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4144733-B1 | CRYSTAL OF M RECEPTOR ANTAGONIST AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | claimed |
| US-12220440-B2 | Drug composition, method for treating infection, disinfecting composition, and drug adjuvant | CITY UNIVERSITY OF HONG KONG (HK) | 2025-02-11 | — | — | US | claimed |
| WO-2024259358-A2 | MODULATION OF FUSOBACTERIUM NUCLEATUM SUBSPECIES ANIMALIS CLADE 2 MICROBES | FRED HUTCHINSON CANCER CENTER (US) | 2024-12-19 | — | — | WO | claimed |
| CN-119106716-A | Power addition operation logic circuit construction method based on DNA domain coding | 郑州西亚斯学院 | 2024-12-10 | — | — | CN | claimed |
| CN-112956127-B | Motor and control device thereof | 梨木政行 | 2024-06-14 | — | — | CN | claimed |
| US-11923727-B2 | Motor and control device therefor | NASHIKI MASAYUKI (JP) | 2024-03-05 | — | — | US | claimed |
| US-20240016883-A1 | DRUG COMPOSITION, METHOD FOR TREATING INFECTION, DISINFECTING COMPOSITION, AND DRUG ADJUVANT | CITY UNIVERSITY OF HONG KONG (HK) | 2024-01-18 | — | — | US | claimed |
| US-20230189810-A1 | AQUEOUS COMPOSITION OF DITHIOCARBAMATE FUNGICIDE | ADAMA MAKHTESHIM LTD. (IL) | 2023-06-22 | — | — | US | claimed |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| US-20040028756-A1 | Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-12 | — | — | US | claimed |
| WO-2004009073-A1 | P-GLYCOPROTEIN INHIBITOR COMPRISING OCTILONIUM BROMIDE AS AN EFFECTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-01-29 | — | — | WO | claimed |
| WO-2003082199-A2 | PLATELET-ACTIVATING FACTOR ANTAGONISTS AS ANALGESIC, ANTI-INFLAMMATORY, UTERINE CONTRACTION INHIBITING, AND ANTI-TUMOR AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1183014-B1 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS | COSMO SPA (IT) | 2003-10-08 | — | — | EP | claimed |
| US-20020193322-A1 | Method of preparing physiologically acceptable aqueous solutions, and solutions thus obtained | BAIOCCHI LEANDRO (IT) | 2002-12-19 | — | — | US | claimed |
| EP-1226831-A1 | Aqueous pharmaceutical solutions with trisubstituted glycyrrhizic acid salts | Baiocchi, Leandro (IT) | 2002-07-31 | — | — | EP | claimed |
| EP-1183014-A1 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS | Cosmo S.p.A. (IT) | 2002-03-06 | — | — | EP | claimed |
| WO-2000076478-A1 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS | COSMO S.P.A. (IT) | 2000-12-21 | — | — | WO | claimed |
| EP-0270503-B1 | UTILIZATION OF BROMURE D'OTILONIUM (DCI) FOR TOPIC APPLICATION IN THE GASTROINTESTINAL TRACT AND RELATIVE PHARMACEUTICAL FORMULATION APPROPRIATE FOR SUCH USE | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1993-09-15 | — | — | EP | claimed |
| US-4978772-A | Applying a mixtue including antifoaming and emulsifying excipients using an endoscipic instrument | A. MENARINI S.A.S. (IT) | 1990-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220440-B2 | Drug composition, method for treating infection, disinfecting composition, and drug adjuvant | PHOSPHO1, O60361, TLR5 | CHRM2 735/4885CHRM1 1106/4885CHRM3 381/4885 |
| US-20240016883-A1 | DRUG COMPOSITION, METHOD FOR TREATING INFECTION, DISINFECTING COMPOSITION, AND DRUG ADJUVANT | PHOSPHO1, O60361, TLR5 | CHRM2 735/4885CHRM1 1106/4885CHRM3 381/4885 |
| US-20230167107-A1 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | CHRM5, CHRM2, CHRM3 | CHRM2 2/4885CHRM1 5/4885CHRM3 3/4885 |
| US-12358908-B2 | Crystals, preparation method and application of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | CHRM2 2/4885CHRM1 5/4885CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.